Fibrobiologics, Inc. (FBLG) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Fibrobiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases, including wound healing, multiple sclerosis, and degenerative disc disease. The company completed a direct listing on Nasdaq on January 31, 2024. This report covers the quarterly period ended June 30, 2024. The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Income/(Loss) | $898,000 | $(7,562,000) | $(4,576,000) |
| Operating Expenses | $3,224,000 | $6,674,000 | $4,358,000 |
| Cash and Cash Equivalents (End of Period) | $5,973,000 | $5,973,000 | $11,378,000 |
| Accumulated Deficit | $(31,919,000) | $(31,919,000) | $(12,447,000) |
| Net Cash Used in Operating Activities | N/A | $(6,222,000) | $(3,661,000) |
Debt and Liquidity: As of June 30, 2024, the company had no outstanding debt. Current liabilities totaled $10.1 million, driven primarily by a $4.8 million warrant liability, a $1.5 million forward contract liability, and a $1.9 million commitment fee payable. The company reported a negative working capital position.
Material Changes vs. Prior Period
- Net Income Volatility: The company reported a net income of $898,000 for Q2 2024, a significant swing from the net loss of $2.16 million in Q2 2023. This was primarily driven by a $5.5 million non-cash gain from the change in fair value of the warrant liability, partially offset by a $1.5 million loss on the forward contract liability.
- Operating Expenses: Total operating expenses increased by 54% year-over-year for the six-month period ($6.7M vs $4.4M). Research and Development (R&D) expenses rose 89% to $1.9 million, and General and Administrative (G&A) expenses rose 42% to $4.7 million. Increases were attributed to hiring, preclinical study costs, and public company compliance costs (legal, accounting, insurance) following the direct listing.
- Capital Structure: Following the direct listing, all Series A Preferred Stock was canceled, and Series B, B-1, and non-voting common stock converted to voting common stock. The company raised $2.8 million in net proceeds from common stock sales under a Share Purchase Agreement in Q1 2024.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for one year from the issuance of the financial statements. The company has an accumulated deficit of $31.9 million and expects to incur significant losses as it advances clinical trials. Continued operations depend on raising additional capital.
- Product Pipeline:
- CYWC628 (Wound Healing): Late pre-clinical stage; planning a Phase 1/2 trial in Australia for 2025.
- CYMS101 (Multiple Sclerosis): Completed Phase 1 in Mexico; seeking strategic partners for Phase 1/2.
- CybroCell (Degenerative Disc Disease): Received FDA IND clearance; planning Phase 1 study in the U.S.
- Financing Activities: The company utilized a Share Purchase Agreement (GEM SPA) to raise capital. In July 2024 (subsequent to period end), the company raised an additional $3.4 million. A $2.0 million commitment fee under this agreement was expensed in Q1 2024.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties. Remediation plans include adding staff and improving controls.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $5.97 million cash balance against the projected burn rate of approximately $6.2 million per six months from operations.
- Non-Cash Gains: Note that Q2 2024 profitability was driven by a $5.5 million non-cash accounting gain on warrant liability valuation, not operational revenue.
- Commitment Fee Obligation: Confirm the status of the $1.9 million commitment fee payable to GEM Global Yield LLC, which is due within one year of the public listing.
- Going Concern Status: Assess the likelihood and terms of future equity or debt financing required to fund clinical trials and operations.
- Internal Control Remediation: Monitor progress on fixing the material weakness regarding segregation of duties in financial reporting.